Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 8 • 2013 ACR/ARHP Annual Meeting
Clinical Evaluation Of Two Anti-Beta₂glycoprotein I Domain 1 Autoantibody Assays To Aid In The Diagnosis and Risk Assessment Of The Antiphospholipid Syndrome
Rohan Willis¹, Michael Mahler², Francesca Pregnolato³, Charis Pericleous⁴, Anisur Rahman⁵, John Ioannou⁶, Ian Giles⁵, Gabriella Lakos², Roger Albesa², Navid Zohoury², Pier-Luigi Meroni⁷ and Silvia S. Pierangeli⁸, ¹Int Medicine/Rheumatology, University of Texas Medical Branch, Galveston, TX, ²Research, INOVA Diagnostics, San Diego, CA, ³Lab of Immunology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁴Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁵Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁶Rayne Institute, University College London, London, UK, London, United Kingdom, ⁷Int Medicine, University of Milan, Milano, Italy, ⁸Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…
Abstract Number: 9 • 2013 ACR/ARHP Annual Meeting
Domain 1 Is The Main Specificity Of Anti-β₂glycoprotein I Antibodies In Systemic Autoimmune Diseases
Laura Andreoli¹, Cecilia Nalli¹, Maria-Orietta Borghi², Francesca Pregnolato³, Alessandra Zanola⁴, Claudia Grossi⁵, Maria Gerosa⁶, Flavio Allegri⁴, Michael Mahler⁷, Gary L. Norman⁷, Pier Luigi Meroni⁸ and Angela Tincani¹, ¹Rheumatology Unit, University of Brescia, Brescia, Italy, ²Lab of immunology, IRCCS Istituto Auxologico Italiano, Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy, ³Lab of Immunology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁴Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁵Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁶Division of Rheumatology, Gaetano Pini Institute, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁷Research, INOVA Diagnostics, San Diego, CA, ⁸Division of Rheumatology, Gaetano Pini Institute, Milano, Italy
Background/Purpose: Anti-β2glycoprotein I antibodies (a-β2GPI) are involved in the pathogenesis of the Antiphospholipid Syndrome (APS). Antibodies to the domain 1 of β2GP1 (a-β2GPI-D1) have been…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].